摘要
目的探讨培美曲塞、吉西他滨联合奈达铂化疗方案治疗晚期非小细胞肺癌的临床疗效及安全性。方法回顾性分析接受化疗的晚期非小细胞肺癌患者138例,其中接受培美曲塞联合奈达铂化疗方案患者69例(培美曲塞组),接受吉西他滨联合奈达铂化疗方案患者69例(吉西他滨组),对比分析2组患者近期疗效以及不良反应发生情况。结果培美曲塞组患者治疗总有效率为33.33%,吉西他滨组患者治疗总有效率为30.43%,2组差异不具统计学意义(P>0.05)。2组患者化疗相关不良反应主要为胃肠反应以及血象改变,培美曲塞组患者脱发、恶心呕吐、血小板下降以及白细胞减少不良反应发生率显著低于吉西他滨组患者(P<0.05);2组间血红蛋白减少、肝肾毒性以及静脉炎不良反应发生率差异不具统计学意义(P>0.05)。治疗后2组患者临床症状评分均有所改善,但2组间差异不具统计学意义(P>0.05)。结论培美曲塞、吉西他滨联合奈达铂化疗方案治疗晚期非小细胞肺癌均可获得较好临床效果,但培美曲塞联合奈达铂化疗方案不良反应较轻,以Ⅰ~Ⅱ度为主,是较为理想的晚期非小细胞肺癌的化疗方案。
Objective To stuyd the clinical efficacy and safety of pemetrexed and gemcitabine combined with nedaplatin chemotherapy in the treatment of advanced non-small cell lung cancer. Methods Retrospective analysis of 138 patients with ad- vanced non-small cell lung cancer who received chemotherapy were selected,69 patients who accepted pemetrexed combined with nedaplatin chemotherapy was pemetrexed group, 69 patients who accepted gemcitabine combined with nedaplatin chemotherapy was gemcitabine group,the short-term efficacy and adverse reactions of the 2 groups were compared and analyzed. Results The total effective rate of the pemetrexed group was 33.33% ,and the total effective rate of the gemcitabine group was 30.43%. The difference between the 2 groups was not statistically significant （P 〉 0.05 ）. chemotherapy related adverse reactions of the 2 groups mainly were gastrointestinal reaction and Hemogram change, the incidence rate of adverse reaction such as alopecia, nause- a, vomiting, decreased platelet and white blood cell reduce in patients of pemetrexed group was lower than that of patients in the gemcitabine group （ P 〈 0.05 ） ; there was no statistically significant difference between the 2 groups in the reduction of hemoglo- bin,liver and kidney toxicity and phlebitis （P 〉 0.05 ）. After treatment, the clinical symptom scores of 2 groups were improved, but the difference between the 2 groups was not significant （ P 〉 0.05）. Conclusion Pemetrexed, gemcitabine combined with nedaplatin platinum based chemotherapy regimens in the treatment of advanced non-small cell lung cancer can obtain better clinical effect,but pemetrexed combined with nedaplatin chemotherapy has lighter adverse reactions, and mainly in the Ⅰ-Ⅱ degree,it is an ideal chemotherapy for advanced non-small cell lung cancer.
出处
《实用癌症杂志》
2017年第10期1648-1650,共3页
The Practical Journal of Cancer
关键词
培美曲塞
吉西他滨
奈达铂
非小细胞肺癌
Pemetrexed
Gemcitabine
Nedaplatin
Non-small cell lung cancer
